Cassava Sciences (NASDAQ:SAVA) crashed nearly 84% following a late-stage trial setback for its lead asset, simufilam, leaving SAVA investors wondering what’s in store for the once-high-flying biotech after its dramatic fall from grace on Monday.

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, failing a clinical trial.

Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had pledged to share the results whether “good, bad or ambiguous.”